Clinical evidence from adequate and well-controlled investigation(s) indicates that the drug may demonstrate substantial improvement on a clinically relevant endpoint(s) over available therapies
Intended to treat serious condition with an unmet medical need
No aspect of the submission likely will require a longer review time (e.g., require a new Risk Evaluation and Mitigation Strategy, etc.)
No chemistry, manufacturing or control information that would require a foreign manufacturing site inspection

Looking For STARs: US FDA Expands Split Real Time Review Amid Low Supplement Interest

More from Review Pathways